-$0.80 EPS Expected for Collegium Pharmaceutical, Inc. (COLL) This Quarter
Wall Street brokerages forecast that Collegium Pharmaceutical, Inc. (NASDAQ:COLL) will report ($0.80) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Collegium Pharmaceutical’s earnings, with the highest EPS estimate coming in at ($0.74) and the lowest estimate coming in at ($0.88). Collegium Pharmaceutical posted earnings of ($1.05) per share in the same quarter last year, which would suggest a positive year over year growth rate of 23.8%. The company is scheduled to report its next quarterly earnings results on Wednesday, August 9th.
On average, analysts expect that Collegium Pharmaceutical will report full year earnings of ($3.10) per share for the current financial year, with EPS estimates ranging from ($3.39) to ($2.86). For the next financial year, analysts forecast that the firm will report earnings of ($1.84) per share, with EPS estimates ranging from ($2.55) to ($1.31). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.98) by $0.19. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $3.55 million.
A number of analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday, March 14th. ValuEngine raised shares of Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Jefferies Group LLC set a $24.00 price target on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Saturday, March 25th. Janney Montgomery Scott reissued a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. Finally, Needham & Company LLC reissued a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, June 9th. Two equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. Collegium Pharmaceutical has a consensus rating of “Hold” and a consensus price target of $22.83.
Collegium Pharmaceutical (NASDAQ:COLL) traded down 1.01% on Tuesday, reaching $12.71. 301,786 shares of the company’s stock traded hands. The stock has a 50-day moving average of $10.09 and a 200 day moving average of $12.74. The firm’s market capitalization is $374.41 million. Collegium Pharmaceutical has a 52 week low of $7.37 and a 52 week high of $20.55.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/11/0-80-eps-expected-for-collegium-pharmaceutical-inc-coll-this-quarter.html.
In other Collegium Pharmaceutical news, insider Paul Brannelly acquired 10,000 shares of the firm’s stock in a transaction on Friday, May 12th. The stock was purchased at an average price of $9.18 per share, with a total value of $91,800.00. Following the completion of the acquisition, the insider now directly owns 110,227 shares in the company, valued at approximately $1,011,883.86. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 25.76% of the company’s stock.
Several institutional investors have recently made changes to their positions in COLL. American International Group Inc. increased its position in shares of Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock valued at $100,000 after buying an additional 2,163 shares during the period. Nationwide Fund Advisors increased its position in shares of Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 1,422 shares during the period. Macquarie Group Ltd. purchased a new position in shares of Collegium Pharmaceutical during the fourth quarter valued at about $127,000. Credit Suisse AG increased its position in shares of Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock valued at $137,000 after buying an additional 1,173 shares during the period. Finally, UBS Group AG increased its position in shares of Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock valued at $139,000 after buying an additional 10,174 shares during the period. 82.30% of the stock is owned by institutional investors.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.